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LETTER TO THE EDITOR
META-ANALYSIS OF ASPIRIN FOR THE PREVENTION
OF PREECLAMPSIA: DO THE MAIN RANDOMIZED
CONTROLLED TRIALS SUPPORT AN ASSOCIATION
BETWEEN LOW-DOSE ASPIRIN AND A REDUCED
RISK OF DEVELOPING PREECLAMPSIA?
Tiago V. Pereira, Martina Rudnicki, Júlia M. P. Soler, and José E. Krieger
The meta-analysis by Ruano et al1 evaluating 17
randomized controlled trials considering the pooled rela-
tive risk (RR) of 16,898 women at high-risk of
preeclampsia receiving acetylsalicylic acid (8679 treatment
and 8219 placebo) suggested that low-dose aspirin (50-150
mg/day) has a small but significant protective effect on the
risk of preeclampsia: Pooled RR = 0.87; 95% confidence
intervals (CI) = 0.79 to 0.96, P = 0.004). This conclusion
relies uniquely on the estimate from the fixed-effects model
using the Mantel-Haenszel method (MH).2 However, we
would like to raise some issues that allow different inter-
pretations from the same meta-analysis.
First, results of a meta-analysis are model-dependent.3
There are potential differences between models in meta-
analysis, since they have distinct properties and assump-
tions,2,4 and can model for different effects.3 Second, be-
cause the choice between fixed- and random-effect mod-
els remains a controversial issue,5 results from both mod-
els should be considered when drawing conclusions from
a meta-analysis,6 especially in cases where heterogeneity
among treatment effects is observed.7 Third, when evidence
for publication bias is not properly considered, results from
meta-analytic studies can be seriously overestimated, yield-
ing misleading conclusions.8
In this regard, we extended further the analysis by
Ruano et al1 and provide an alternative interpretation from
the same data set, illustrating practical consequences of fit-
ting different types of statistical modeling in meta-analy-
sis. Furthermore, we illustrate that changes in model se-
lection substantially affect the outcome of a meta-analy-
sis, particularly when the null hypothesis of homogeneity
among treatment effects is rejected.
It is well established that in the fixed-effects model, the
true treatment difference is often considered to be the same
for all trials.2 In other words, fixed-effects models assume
homogeneity among study estimates, whereas the variance
of each trial estimate is based uniquely on sampling varia-
tion within the trial (within-study variance). In the random-
effects model, however, the true treatment difference in
each trial is itself assumed to be a random variable with a
normal distribution.4 In addition, a second component of
the total variance, the variance between-study, is estimated.
Thus, in the random-effects model both within-study and
between-study variances are taken into account in the as-
sessment of the uncertainty (confidence intervals). While
estimates based on fixed-effect models are specific to the
particular trials included in the meta-analysis, results of the
random-effects models are more amenable to generaliza-
tion in terms of population.6 When there is no heterogene-
ity between trials, both models tend to provide the same
overall estimate and standard error.5 However, this is not
true when heterogeneity is present.5 As the heterogeneity
increases, the standard error of the common estimate from
the random effects model becomes wider than that from
the fixed-effects model.4 Thus, the difference between the
overall estimates from the two approaches depends strongly
on the amount of between-study variation among trials.6
Such properties have led some authors to recommend the
incorporation of the between-study variance through an
implementation of the random-effects model in meta-analy-
sis when heterogeneity is observed.9 In fact, published evi-
dence suggests the broad use of random-effects models for
the combination of both homogeneous and mild heteroge-
neous trials,7 whereas the combination of highly heteroge-
neous studies should be avoided.6
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Hence, although Ruano et al1 correctly tested the het-
erogeneity among effect sizes of individual studies, they
have not considered adequately this finding. According to
these authors, the homogeneity among treatment effects
was formally assessed through the Cochran´s Q statistic,4
which is a weighted sum of squares of the deviations of
individual study RR estimates from the overall estimate.
This statistic estimates the probability that the observed
pattern of results may have occurred simply by chance.
When the RRs are homogeneous, the Q statitic follows a
chi-squared distribution with r - 1 degrees of freedom (df),
where r is the number of studies. Unfortunately, heteroge-
neity tests in meta-analysis lack power, and statistical sig-
nificance set at 10% is advocated.7,10 Running Ruano et al1
analysis again, we observed a significant evidence for het-
erogeneity both in the asymptotic (χ2 = 25.86, df = 16, P
= 0.056) and the parametric bootstrap version (1000 repli-
cations, P = 0.049) of the Q statistic. To further explore
heterogeneity, we derived the proportion of the total vari-
ance of the pooled effect measure7 (Ri statistic) due to be-
tween-study variance (random-effects model), and quanti-
fied the I2 metric,11 which takes values between 0% and
100%, with higher values denoting greater degree of het-
erogeneity. Derivation of the Ri statistic suggests that al-
most half (46%) of the total variance from the meta-analy-
sis of Ruano et al.1 came from between-study variance. In
addition, the I2 metric detonates the presence of moderate
heterogeneity (38.1%). Thus, we provide compelling evi-
dence for a mild to moderate heterogeneity among study
results, suggesting that the conclusion of Ruano et al1
should not be based uniquely on a fixed-effects model. In
this respect, we applied to the same data set a random-ef-
fects model using the DerSimonian-Laird method (DL).4
Surprisingly, we found no convincing evidence for a pro-
tective effect of low-dose aspirin under this model at 5%
(DL Common RR = 0.835; 95% CI = 0.697 to 1.001, P =
0.051). In order to scrutinize the heterogeneity, we fitted a
random-effects regression model (meta-regression) of the
log RR.12 This regression model investigates whether any
study feature influences the magnitude of the relative risk
in individual studies. Year of publication, impact factor (ac-
cording to the Journal of Citation Reports 2004), aspirin
dose, sample size, and gestation age of inclusion were as-
signed as study-level covariates. An exploratory stepwise
backward random-effects meta-regression reveals that year
of publication and total sample size were associated with
reduced magnitudes of RR (year of publication slope co-
efficient = 0.07; 95% CI = 0.03 to 0.11, P < 0.001 and
total sample size slope coefficient = 4 ×  10-5; 95% CI =
6.9 
×
 10-6 to 7×  10-5, P = 0.02). These meta-regression
coefficients are estimates of the expected increment in the
log RR per unit increase in the covariate. In other words,
in the studies of low-dose aspirin for prevention of
preeclampsia (high-risk women) the log RR is estimated
to rise 0.07 per year increase and to increase = 4  10-5
per individual added in each the study. These findings led
us to a perform sensitivity analysis considering total sam-
ple size.13 In this analysis we separately explored studies
with sample size >1000 and <=1000. By combining RR
from these 14 small trials (1549 treatment and 1704 pla-
cebo) with sample sizes equal or smaller than 1000 sub-
jects, we obtained a marginally significant but stronger pro-
tective effect of low-dose aspirin in the prevention of
preeclampsia (DL common RR = 0.67; 95% CI = 0.48 to
0.93, P = 0.02, Q statistic, χ2 = 23.15, df = 13, P = 0.04).
In contrast, by combining the 3 larger studies totaling
13645 individuals (7130 treatment and 6515 placebo) we
found no evidence for a role of low-dose aspirin in
preeclampsia prevention (MH common RR = 0.91; 95%
CI = 0.82 to 1.02, P = 0.094, Q statistic parametric
bootstrap version with 1000 replications, P = 0.34). Like-
wise, stratification of studies by samples sizes >500 and
<=500 yielded virtually the same results.
Disagreements between large and smaller trials are com-
patible with the presence of publication bias,8 a tendency
on the part of investigators, editors, and reviewers to pub-
lish preferentially studies with positive results (“statistically
significant results”).6,8,14 In fact, it is well recognized that
earlier trials tend to have smaller samples, less methodo-
logical quality, and to give more impressive estimates of
treatment effect than subsequent research.13 However, pub-
lication bias may lead to overestimation of treatment ef-
fects in meta-analysis, since negative, nonstatistically-sig-
nificant small trials are less likely to be published.8 There-
fore, we tested graphically and formally the presence of
publication bias in this set of 14 studies. We carried out
analysis of publication bias using the Egger’s regression
asymmetry statistics8 and the Begg-Mazumdar adjusted rank
correlation test.15 In addition, funnel plot asymmetry was
also used.6,8 The funnel plot is based on the fact that pre-
cision in estimating the underlying treatment effect will in-
crease as the sample size of the included trials increases.6
Results from small studies will scatter widely at the bot-
tom of the graph, with the spread narrowing among larger
studies.8 In the absence of bias, the plot will resemble a
symmetrical inverted funnel. Conversely, if negative small
trials are less likely to be published, the graph will tend to
be skewed (asymmetric).6
Although heterogeneity may affect these statistics,8,16
both tests showed reasonable evidence for publication bias
in the set of 14 small studies (Begg-Mazumdar’s test, P =
0.02; Egger’s statistics, P = 0.001). Additionally, as de-
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picted in Figure 1, the visual inspection of the funnel plot
comparing precision (1/Standard Error of RR) against treat-
ment effect (Log RR) reveals noticeable asymmetry (all 17
trials included), reinforcing the probable presence of pub-
lication bias.
These results do not completely rule out a role for as-
pirin in the preeclampsia prevention. However, taken to-
gether, the presence of heterogeneity, the conflicting results
between large and smaller trials, the lack of robustness be-
tween fixed- and random-effects models, and the putative
presence of publication bias call into question the reliabil-
ity of the evidence for a protective effect of low-dose as-
pirin on the risk of preeclampsia.
In conclusion, despite the 20 years of research since the
first report, the relationship between aspirin treatment and
a reduced risk of preeclampsia in women considered at
high-risk still remains an unresolved issue. Further ap-
proaches, such as meta-analysis considering language bias
or individual patient data meta-analysis,17 are required.
Figure 1 - Funnel plot of 17 studies investigating the effect of low-dose
aspirin for preeclampsia prevention (high-risk women) previously analyzed
by Ruano et al.1 Vertical axis depicts the precision represented here by the
inverse of the standard error (SE) of relative risk (RR). Horizontal axis
represents the logarithm of RR. Solid line denotes null effect and dotted line
is the pooled RR under a fixed-effects model (Mantel-Haenszel method).
“Positive” studies denote trials showing a protective effect of aspirin in the
prevention of preeclampsia (high-risk women), but not necessarily reflecting
“statistically significant” studies. “Negative” studies represent trials showing
no beneficial effects of aspirin in preeclampsia (high-risk women). Visual
inspection of the funnel plot suggests asymmetry. At the bottom right: are
small trials showing no beneficial effects missing?
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